Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response Peng Jiang, Shengqing Gu, Deng Pan, Jingxin Fu, Avinash Sahu, Xihao Hu, Ziyi Li, Nicole Traugh, Xia Bu, Bo Li, Jun Liu, Gordon J. Freeman, Myles A. Brown, Kai W. Wucherpfennig & X. Shirley Liu Nature Medicine (2018) | Abstract Cancer treatment by immune checkpoint blockade (ICB) […] Read More
IMMUNOTHERAPY FOR ALZHEIMERS: EXCITING NEW CLINICAL TRIAL- Raymond Rupert MD, MBA. Rupert Case Management Inc.
U of T neurology professor Sandra Black is cautiously optimistic around positive results of a new Alzheimer’s drug reported last week in the high impact journal Nature. “It’s close to being very promising and potentially very exciting,” Black, a senior scientist at Sunnybrook Health Sciences Centre, told the Toronto Star, noting that Sunnybrook is a clinic site for […] Read More
IMMUNOTHERAPY AT THE LEADING EDGE: The new cancer treatment developed at Penn uses gene-editing to modify T cells so they more effectively target certain cancers other than leukemia. Penn appears to have filed a patent on the idea last October, according to European patent records. A proposal for a small safety study will be […] Read More
Something for patients and oncologists to consider in their future treatment plans. Vaxil Biotherapeutics has developed and is testing a cancer vaccine. Immucin is the vaccine. The vaccine is very innovative. It attacks the MUC1 marker on the tumour cell. About 90% of tumours have MUC1 markers. By attacking this marker, it makes the tumour […] Read More